Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Recombinant Human Thrombopoietin (rh-TPO)
in combination with Rituximab are effective and safe in the management of
Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).
Phase:
Phase 3
Details
Lead Sponsor:
Ming Hou
Collaborators:
Chinese Academy of Medical Sciences First Affiliated Hospital, Sun Yat-Sen University Peking Union Medical College Hospital Shandong Provincial Hospital West China Hospital Wuhan Union Hospital, China Zhejiang University